Letter to the Editor: Central nervous system relapse rate and dose intensification in poor risk metastatic germ cell tumours—A comment on: ‘Patterns of relapse in poor prognosis germ cell tumours in the GETUG-13 trial: Implications for the assessment of brain metastases.’ by Loriot and colleagues-Reference-Cited by-同舟云学术

Letter to the Editor: Central nervous system relapse rate and dose intensification in poor risk metastatic germ cell tumours—A comment on: ‘Patterns of relapse in poor prognosis germ cell tumours in the GETUG-13 trial: Implications for the assessment of brain metastases.’ by Loriot and colleagues

Published:2018-05 Issue: Volume:95 Page:102-103
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Alifrangis Constantine^ORCID,Wilson Peter,Shamash Jonathan

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference6 articles.

1. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial;Fizazi;Lancet Oncol,2014

2. Brain metastases associated with germ cell tumors may be treated with chemotherapy alone;Hardt;Cancer,2014

3. Penetration of etoposide into human malignant brain tumors after intravenous and oral administration;Kiya;Cancer Chemother Pharmacol,1992

4. Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: implications for assessment of brain metastases;Loriot;Eur J Cancer,2017

5. Penetration of VP 16-213 into cerebrospinal fluid after high-dose intravenous administration;Postmus;J Clin Oncol,1984

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Brain metastases from germ cell tumor: time to reconsider radiotherapy?;Critical Reviews in Oncology/Hematology;2020-06

2. Dose-dense chemotherapy for untreated poor-prognosis and relapsed germ-cell tumours: an 18-year experience with GAMEC chemotherapy;BJU International;2020-05-04